Expression of Ferredoxin1 in cisplatin‑resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatin

Autonomous and intercellular chemokine signaling elicited from mesenchymal stem cells regulates migration of undifferentiated gastric cancer cells

(2022) Daiki Okamoto et al.   GENES TO CELLS

Copper induces cell death by targeting lipoylated TCA cycle proteins

(2022) Peter Tsvetkov et al.   SCIENCE

Upregulation of the Long Noncoding RNA CASC10 Promotes Cisplatin Resistance in High-Grade Serous Ovarian Cancer

(2022) Ricardo Noriega-Rivera et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker

(2022) Chi Zhang et al.   Frontiers in Genetics

High co‐expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer

(2022) Xiaodong Wu et al.   BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY

Role of ferroptosis in cisplatin-induced acute nephrotoxicity in mice

(2021) Yasumasa Ikeda et al.   JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY

Oncogenic E6 and/or E7 proteins drive proliferation and invasion of human papilloma virus‑positive head and neck squamous cell cancer through upregulation of Ror2 expression

(2021) Mehmet Avincsal et al.   ONCOLOGY REPORTS

FDX1 can Impact the Prognosis and Mediate the Metabolism of Lung Adenocarcinoma

(2021) Zeyu Zhang et al.   Frontiers in Pharmacology

Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study.

(2020) Aurelien Marabelle et al.   JOURNAL OF CLINICAL ONCOLOGY

ROS-Dependent Lipid Peroxidation and Reliant Antioxidant Ferroptosis-Suppressor-Protein 1 in Rheumatoid Arthritis: a Covert Clue for Potential Therapy

(2020) Zhaoxiang Xie et al.   INFLAMMATION

Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome

(2020) Robert L. Hollis et al.   Nature Communications

Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion

(2019) Yang Li et al.   CELL DEATH AND DIFFERENTIATION

Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11

(2019) Xueting Lang et al.   Cancer Discovery

FSP1 is a glutathione-independent ferroptosis suppressor

(2019) Sebastian Doll et al.   NATURE

The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis

(2019) Kirill Bersuker et al.   NATURE

Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective

(2019) Paul J. Derry et al.   PROGRESS IN NEUROBIOLOGY

DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer

(2018) Yunxiao Meng et al.   CANCER LETTERS

The ferroptosis inducer erastin irreversibly inhibits system xc− and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells

(2018) Mami Sato et al.   Scientific Reports

Ferroptosis: A Novel Anti-tumor Action for Cisplatin

(2018) Jipeng Guo et al.   Cancer Research and Treatment

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer

(2018) Jing Sun et al.   ONCOGENE

Role of Mitochondria in Ferroptosis

(2018) Minghui Gao et al.   MOLECULAR CELL

5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent Disease

(2016) M. K. Wilson et al.   ANNALS OF ONCOLOGY

Ferroptosis: process and function

(2016) Y Xie et al.   CELL DEATH AND DIFFERENTIATION

Regulation of Ferroptotic Cancer Cell Death by GPX4

(2014) Wan Seok Yang et al.   CELL

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

(2014) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: A prospective analysis

(2013) Vanessa L. Beesley et al.   GYNECOLOGIC ONCOLOGY

Emerging landscape of oncogenic signatures across human cancers

(2013) Giovanni Ciriello et al.   NATURE GENETICS

Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death

(2012) Scott J. Dixon et al.   CELL

Both human ferredoxins 1 and 2 and ferredoxin reductase are important for iron-sulfur cluster biogenesis

(2011) Yanbo Shi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Humans possess two mitochondrial ferredoxins, Fdx1 and Fdx2, with distinct roles in steroidogenesis, heme, and Fe/S cluster biosynthesis

(2010) A. D. Sheftel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

(2009) Michael A. Bookman et al.   JOURNAL OF CLINICAL ONCOLOGY